DailyIQ
Last updated10 minutes ago

GMED·Globus Medical Inc. Class A

$76.34
+0.10 (+0.13%)
Overnight$76.32-0.02 (-0.03%)
High
$76.71
Open
$76.70
Market Cap
10.02B
52W High
$101.40
Low
$74.98
P. Close
$76.34
P/E
18.72
52W Low
$56.32
Fwd P/E
14.14
DailyIQ Est.
$104.13
Inst. Ownership
39.4%
Short Interest
6.42%
Days to Cover
5.1
Technical Score (1D)
78
BULLISH
News Sentiment
62
BULLISH
A technical score of 78 and a BUY signal on the 1D chart keep Globus Medical Inc. Class A (GMED) firmly in bullish territory. Momentum is strong and sentiment at 62 is aligned with the trend - both inputs are aligned and pointing in the same direction. Price action is constructive. Trend continuation setups like this reward discipline over aggression: the better trades tend to come from entries near $73.27 rather than chasing current levels. $79.37 remains the upside reference, and a sustained close above it would add confidence to the continuation thesis. Trends this clean don't need much active management - the main risk is over-trading around a setup that's already working. Trailing risk toward $73.27 and letting $79.37 act as the next checkpoint, rather than taking profits prematurely on strength, is typically the higher-expectancy approach when strong trend structure and aligned with sentiment are both confirming the same direction.
LOW TARGET
$84 +10.1%
2 analysts
MEAN TARGET
$101 +32.2%
12 analysts
HIGH TARGET
$125 +63.8%
11 analysts
PRICE RANGE
$84.00 - $125.00
SB / B / H / S / SS
4/12/7/1/1
DAILYIQ EST.
$104.13 (+36.4%)
Bought (1Y)
0 shares
$0
Sold (1Y)
80,000 shares
$6.4M
TOBIN JAMES R-
Option Exercise15,000 shares2026-09-15
TOBIN JAMES R-
Sell30,000 shares2026-09-15
TOBIN JAMES R-
Option Exercise15,000 shares2026-09-15
ZARRILLI STEPHEN T-
Option Exercise25,000 shares2026-08-18
ZARRILLI STEPHEN T-
Sell25,000 shares2026-08-18
92/ 100
Strong bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
67.4%
Net Margin
18.3%
Revenue CAGR
16.7%
Current Ratio
4.26x
Return on Equity
11.8%

EPS

EstBeatMiss
$0.72$0.85$0.99$1.12$1.26Q3'25Q3'26
QtrEstActual+/−
Q3'26$1.20 - -
Q3'25$0.78$1.18+51.1%

Revenue

EstBeatMiss
$763M$776M$789M$801M$814MQ3'25Q3'26
QtrEstActual+/−
Q3'26$808M - -
Q3'25 - $769M -

Market Data

GMED Stock Snapshot

BULLISH78/100
$76.32−$0.02 (0.0%)
Market cap
10.02B
P/E ratio
18.7
Day range
$74.98 – $76.71
News sentiment
62/100 · Bullish
Analyst target
$100.92 (+32.2%)
Consensus
Buy · 25 analysts
52-week range+35.5% off low · -24.7% from high
$56.32$101.40
Price $76.32 DailyIQ Est. $104.13

GMED's technical picture is constructive, with trend and momentum pointing the same direction. Earnings and guidance carry more weight than macro data at this capitalisation.

Behaviour On Record

What GMED's own history says about today's numbers

Realized volatility (21d)
29.1% 50th pct
Below its peak
-24.6%
vs 200-day average
-11.7%
Up days (1y)
47%

Globus Medical Inc. Class A is currently running 29.1% annualised volatility over the last 21 sessions. Measured against GMED's own 13 years of daily returns rather than a market-wide average, that is the 50th percentile — close to its own typical level, against a typical reading of 28.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

GMED is trading -24.6% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -27.2%, and the deepest was -45.0% in 2023. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits -11.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 15th percentile — a narrower gap than it typically runs. Over the past year GMED closed higher on 47% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 13 years of records, GMED finished the month higher 9 of 13 times, with a median return of +4.7% and an average of +3.6%. Its strongest month historically has been November at +8.6% on average, its weakest September at -3.1%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: GMED has opened more than 2% away from the prior close in 192 of 3,266 sessions (5.9% of the time), with the largest gaps running +17.5% and -13.0%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,267 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against GMED's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of GMED's sector?

Globus Medical Inc. Class A sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving).

Sector rank
#4 of 12
Sector state
Improving
Sector rotation score
73

Options Market

What is the options market pricing for GMED?

CallsPuts

For Globus Medical Inc. Class A's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.24), with at-the-money implied volatility around 90.8%. The options market is pricing roughly a ±5.4% move by that expiry — a range of about $71.59–$79.79.

Put/call ratio (2026-10-16)
0.24
ATM implied volatility
90.8%
Total open interest
1,209
Expected move by 2026-10-16
±5.4% ($71.59–$79.79)

Analyst Rating Changes

Are analysts turning bullish or bearish on GMED?

RBC Capital most recently reiterated its rating on Globus Medical Inc. Class A to Outperform on Oct 1, 2026 with a price target of $85 (from $115). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
RBC Capital — Outperform
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 1, 2026RBC CapitalMaintainedOutperform$115 → $85
Aug 7, 2026Wells FargoMaintainedOverweight$103 → $99
Jul 28, 2026UBSInitiatedNeutral$82
Jul 16, 2026Truist SecuritiesMaintainedBuy$115 → $100
Jul 13, 2026RBC CapitalMaintainedOutperform$120 → $115
Jul 9, 2026BMO CapitalInitiatedOutperform$94
Jul 8, 2026StifelMaintainedHold$95 → $80
Jun 15, 2026Piper SandlerMaintainedOverweight$115 → $100
May 8, 2026RBC CapitalMaintainedOutperform$115 → $120
May 8, 2026Wells FargoMaintainedOverweight$104 → $103
May 8, 2026NeedhamMaintainedBuy$114 → $117
Feb 26, 2026Wells FargoMaintainedOverweight$98 → $104

ETF holders

ETFs holding GMED

News Sentiment Analysis

Sentiment gathered from recent headlines

62/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Globus Medical reported a strengthening market position in musculoskeletal solutions, driven by a robust pipeline of over 60 active projects and recent product launches across implants, biologics, accessories, and instruments. The company’s debt‑free balance sheet and substantial cash reserves enable continued investment in R&D, sales, and manufacturing expansion. These developments reinforce the company’s competitive moat and support a positive outlook for future growth.
What did this article say?
Globus Medical’s latest analyst consensus lowered its fair‑value estimate from $103.23 to $100.92, reflecting a cautious outlook on spine procedures and hospital spending. Some analysts praised earnings power and integration progress, while others highlighted softer segment trends that could dampen future growth. The mixed commentary suggests a modest headwind for the company’s valuation, though overall sentiment remains neutral to slightly negative.
What did this article say?
Globus Medical, Inc. (GMED) expanded its market share in the musculoskeletal solutions sector, driven by robust performance of its implantable devices, biologics, accessories, and surgical instruments. The company’s product innovation and debt‑free balance sheet further enhanced its attractiveness to investors. Despite foreign exchange headwinds, GMED’s earnings consistently beat estimates over the past four quarters, with an average surprise of 27.9%. The firm’s earnings yield of 6.5% outpaced the industry’s negative 1.9% yield, underscoring its financial strength.
What did this article say?
Globus Medical demonstrated robust return on invested capital and maintained a low debt profile, underscoring its financial strength. The company’s growth trajectory appears sustainable, supported by a diversified product portfolio and expanding market presence. Analysts noted that the firm’s valuation remains attractive relative to peers, suggesting potential upside for investors. These factors collectively reinforce a positive outlook for GMED’s future performance.
What did this article say?
On October 6, 2026, Zacks highlighted Globus Medical (GMED) as part of a broader industry analysis on generative AI adoption. The report noted that GMED is moving from experimental to practical applications of GenAI, using it to generate synthetic medical images, simulate disease progression, and design potential drug molecules. The article emphasized that over 80% of U.S. healthcare leaders have deployed GenAI use cases, positioning GMED to benefit from accelerated drug development and improved patient engagement. Regulatory developments, such as the EU AI Act, were also discussed as shaping the industry landscape. Overall, the piece portrayed GMED’s AI initiatives as a positive driver for future growth.
What did this article say?
RBC Capital analyst Kendall Au reduced Globus Medical’s price target from $115 to $85 while keeping an Outperform rating. The downgrade reflects concerns about the company’s valuation relative to peers and potential earnings pressure. The move signals a negative outlook for the stock, suggesting investors may see limited upside in the near term.
What did this article say?
Zacks analysis compared Globus Medical (GMED) and Integer (ITGR) for value investors, highlighting GMED’s higher Zacks Rank of #1 (Strong Buy) versus ITGR’s #3 (Hold). The report noted GMED’s positive earnings estimate revisions and strong value metrics, suggesting an improving earnings outlook. The comparison emphasized GMED’s undervaluation relative to its peers, positioning it as a more attractive option for value-focused portfolios. The article concluded that GMED’s stronger fundamentals and valuation make it a better buy for investors seeking value opportunities.
What did this article say?
Fresenius Medical Care AG & Co. (GMED) announced a strategic shift in its China operations, concentrating on advanced in‑center dialysis and critical‑care technologies while trimming less profitable portfolio items. The company earmarked €110 million for one‑time restructuring costs and emphasized its local manufacturing and design capabilities to support the move. Management projected that the focused approach would strengthen competitive positioning and accelerate profitable growth in the Chinese dialysis market. The announcement was well received by investors, with shares rising modestly following the disclosure.
What did this article say?
Globus Medical (GMED) experienced a 10% decline in share price over the past month and a 5% drop over the past three months, drawing investor attention. The company’s 1‑year total shareholder return of 32.5% and 3‑year return of 50.8% highlight that long‑term investors have still earned substantial gains despite the recent pullback. The recent price movement suggests a temporary cooling of momentum, while the broader market context indicates that the decline may be relative to peers. The data imply a modest negative short‑term outlook, with no immediate catalyst for a deeper downturn.
What did this article say?
Globus Medical’s stock fell 10.3% over the past six months, lagging behind the S&P 500’s 21.4% gain. The decline reflects investor concerns about the company’s recent performance, despite its global presence and a portfolio of more than ten new products launched in 2023. Analysts note that constant‑currency revenue has been a positive driver, suggesting underlying demand remains resilient. The mixed signals leave the market uncertain about GMED’s near‑term trajectory.

Technical Analysis

Real-time indicators across multiple timeframes

78
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $4.23B combined position · 18 adding, 7 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▼ Sell10,549,4558.03%$921.07M2026-01-29
BlackRock, Inc.▲ Buy10,806,7248.23%$853.84M2026-08-07
Janus Henderson Group plc▲ Buy7,623,0955.80%$656.83M2026-05-18
Invesco Ltd.▼ Sell4,309,7713.28%$340.52M2026-08-14
JPMorgan Chase & Co▲ Buy2,743,8502.09%$230.76M2026-08-12
AllianceBernstein L.P.▲ Buy2,380,3441.81%$205.09M2026-08-14
Geode Capital Management, LLC▲ Buy2,153,0141.64%$170.15M2026-08-12
Goldman Sachs Group Inc▲ Buy1,781,6081.36%$140.76M2026-08-14
William Blair Investment Management, LLC▼ Sell1,284,8960.98%$101.52M2026-08-12
Norges Bank▲ Buy1,127,0510.86%$89.05M2026-08-12
Morgan Stanley▲ Buy1,094,7530.83%$86.50M2026-08-13
Wells Fargo & Company▲ Buy996,6170.76%$78.74M2026-08-14
Northern Trust Corp▲ Buy880,6330.67%$69.58M2026-08-13
FMR LLC (Fidelity)▲ Buy768,0510.58%$60.68M2026-08-13
Bank of America Corp▲ Buy737,1130.56%$58.24M2026-08-14
Capital World Investors▲ Buy590,6120.45%$46.66M2026-08-12
Bares Capital Management, Inc.▲ New521,1290.40%$29.85M2025-11-14
Bridgewater Associates, LP▲ Buy351,9740.27%$27.81M2026-08-14
Gotham Asset Management, LLC▲ Buy283,0580.22%$22.36M2026-08-14
Renaissance Technologies LLC▼ Sell196,9180.15%$15.56M2026-08-13
Marshall Wace, LLP▼ Sell188,5410.14%$14.90M2026-08-13
Man Group plc▲ Buy55,3200.04%$4.37M2026-08-14
Prudential Financial Inc▼ Sell54,2560.04%$4.29M2026-08-12
AQR Capital Management LLC▼ Sell36,5340.03%$2.85M2026-08-14
Wellington Management Group LLP▲ Buy35,0660.03%$2.77M2026-08-14
Q2 2026 flow:2.99M sh bought ($241.74M)2.11M sh sold ($165.87M)net +883.4K sh (+$75.87M)
Congressional Trading Activity
5 disclosed trades · ~$64.5K est. traded value · 2 buys, 3 sells
MemberChamberStateTypeAmountTradedFiled
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-09-032026-10-12
Gilbert CisnerosHouseCA31▲ Buy$15K - $50K2026-08-192026-09-10
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-07-102025-08-13
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2025-04-092025-05-14
Thom TillisSenateNC▼ Sell$1K - $15K2015-02-132015-02-26